TRIALS Flashcards
This study found that targeting HbA1c <6.0% resulted in higher risk of cardiovascular and all-cause mortality as compared with standard therapy (i.e., targeting HbA1c between 7.0-7.9%).
ACCORD trial
Rivaroxaban is non-inferior to warfarin in preventing strokes and systemic embolism.
ROCKET AF trial
Intensive glycemic control in critically ill patients significantly increases 90-day mortality when compared to conventional glycemic control.
NICE-SUGAR trial
Adding 25 mg of spironolactone to standard therapy reduces all-cause mortality in heart failure patients with an ejection fraction <35%
RALES trial
Digoxin significantly reduced hospitalizations but had no significant effect on mortality when used to treat patients with systolic heart failure
DIG trial
In severe coronary artery disease, CABG is superior to PCI in reducing the need for repeat vascularization
SYNTAX trial
Rate-control, along with anticoagulation, should be the main approach to managing patients with atrial fibrillation. Compared to rhythm-control, rate-control resulted in a lower incidence of adverse events and no significant difference in mortality.
AFFIRM trial
In patients with symptomatic heart failure and reduced ejection fraction, the addition of metoprolol to standard therapy reduced all-cause mortality by 34% compared to placebo.
MERIT-HF trial
There was no significant difference in the composite rate of death, nonfatal myocardial infarction, or rehospitalization for angina in patients with acute coronary syndromes treated with early invasive versus selectively invasive strategies
ICTUS trial
Carvedilol significantly reduced mortality from cardiovascular causes and recurrent non-fatal MI.
CAPRICORN trial
High-dose atorvastatin was associated with a 16% reduction in death or major cardiovascular events compared to standard pravastatin therapy following an acute coronary syndrome.
PROVE IT trial
There were no significant differences in the rates of fatal coronary heart disease or nonfatal myocardial infarction when comparing thiazide diuretics with ACE-Is or CCBs in hypertension management.
ALLHAT trial
For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications. Strict control of blood pressure in type 2 diabetes mellitus reduces the risk of both microvascular and macrovascular complications, along with diabetes-related mortality.
UKPDS
In patients with renal insufficiency and elevated baseline proteinuria (≥1 g/day in moderate insufficiency, ≥3 g/day in severe insufficiency), lower blood pressure targets significantly delayed the progression of renal disease
MDRD trial
In patients with severe acute respiratory distress syndrome (ARDS), prone-positioning significantly reduced 28-day and 90-day mortality when compared with patients remaining in supine position.
PROSEVA trial
